Drug Trial Radar · NCT06179108
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
359
Actual
Start
Nov 29, 2023
Primary completion
Dec 4, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- LB Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.
Conditions
- Schizophrenia
Interventions
LB-102Drug
LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 4 in the PANSS Total ScoreTime frame: Baseline to Day 28 (4 weeks)
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Pillar Clinical Research
Bentonville, Arkansas
Woodland Internation Research Group
Little Rock, Arkansas
Woodland Research Northwest
Rogers, Arkansas
CelExel Clinical Innovations
Bellflower, California
Synexus
Cerritos, California
ProScience Research Group
Culver City, California
CelExel CNS
Garden Grove, California
Synergy Research
Lemon Grove, California
CenExel CIT Riverside
Riverside, California
NRC Research Institute
Santa Ana, California
Behavioral Clinical Research, Inc.
Hollywood, Florida
CenExel RCA
Hollywood, Florida
Segal Institute for Clinical Research
Miami Lakes, Florida
CenExel ACMR
Atlanta, Georgia
CenExel iResearch
Decatur, Georgia
Uptown Research Institute
Chicago, Illinois
Pillar Clinical Research
Chicago, Illinois
CenExel CBH
Gaithersburg, Maryland
CenExel HRI
Berlin, New Jersey
Richmond Behavioral Associates
Staten Island, New York
Midwest Clinical Research Center
Dayton, Ohio
Neuro-Behavioral Clinical Research
North Canton, Ohio
Community Clinical Research
Austin, Texas
InSite Clinical Research
DeSoto, Texas
Pillar Clinical Research
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.